Drug Label & Ingredient
Review Services
An FDA Drug Label & Ingredient Review is a regulatory audit of an OTC or prescription drug product label and its declared ingredients against U.S. Food and Drug Administration labeling requirements before the product enters U.S. commerce. The review verifies compliance with 21 CFR Part 201 — including the OTC Drug Facts panel under 21 CFR 201.66, principal display panel rules, established ingredient names, warnings, directions, and any applicable OTC monograph. It catches misbranding risks before the FDA does, so artwork, claims, and ingredient declarations can be corrected at print stage instead of after enforcement. Without it, drug products are exposed to misbranding under FD&C Act §502 — triggering FDA Warning Letters, Import Alert listing, mandatory relabeling, recalls, and removal from Amazon, Walmart, and Shopify.
Every OTC and prescription drug product marketed in the United States must carry an FDA-compliant label. Non-compliant labeling can result in misbranding violations, import holds, and market delays. FDA Registration Assistance reviews your drug product labels and ingredient declarations against current FDA requirements — identifying compliance gaps before your product reaches the market.
What Is FDA Drug Label Compliance & Why Does It Matter?
FDA drug labeling regulations require that every drug product marketed in the United States carries accurate, complete, and properly formatted label information. OTC drug products must comply with the FDA Drug Facts Label format established under 21 CFR Part 201, while prescription drug products must meet separate labeling requirements. Non-compliant labels can result in misbranding violations, import detentions, product recalls, and removal from the market.
FDA Registration Assistance reviews your drug product labels and ingredient declarations against current FDA labeling requirements — verifying format, content, claims, warnings, and active ingredients. Our review identifies compliance gaps before FDA review, reducing the risk of regulatory action or market delays for your drug products.
- OTC drug products must comply with the FDA Drug Facts Label format under 21 CFR Part 201
- Labeling violations can result in misbranding enforcement, import holds, and recalls
- Active ingredients, warnings, directions, and claims must all meet current FDA standards
- Labels must be updated whenever formulation, claims, or applicable FDA guidance changes
Drug Label & Ingredient Compliance Review Services
Everything OTC and prescription drug companies need to ensure their product labels and ingredients meet current FDA requirements.
OTC Drug Facts Label Review
FDA Registration Assistance reviews your OTC drug product labels against the FDA Drug Facts Label requirements under 21 CFR Part 201 — verifying format, required headings, active ingredients, warnings, directions, and claims for full compliance.
Ingredient Declaration Review
FDA Registration Assistance reviews your drug product ingredient declarations to ensure active and inactive ingredients are listed correctly, in the proper format, and in compliance with current FDA requirements and applicable OTC monograph standards.
Compliance Gap Identification
FDA Registration Assistance identifies labeling compliance gaps before FDA review — flagging non-compliant claims, missing warnings, incorrect formatting, or ingredient issues that could result in misbranding violations, import holds, or product delays.
Label Update & Reformulation Support
When your drug product formulation, claims, or applicable FDA guidance changes, your label must be updated accordingly. FDA Registration Assistance reviews updated labels to ensure all changes meet current FDA labeling requirements before relaunch.
Trusted FDA Drug Label & Ingredient Compliance Partner
Helping OTC and prescription drug companies ensure their labels and ingredients meet FDA requirements — before regulatory issues arise.
How Our Drug Label Review Service Works
A simple four-step process to review your drug product labels and ensure full FDA compliance before market.
Submit Your Label & Product Details
Provide your drug product label, ingredient list, and product details. FDA Registration Assistance reviews your submission to ensure everything is ready for a complete compliance review.
Label & Ingredient Review Conducted
FDA Registration Assistance reviews your label against current FDA requirements — checking format, headings, active and inactive ingredients, claims, warnings, and Drug Facts Label compliance.
Compliance Report Delivered
FDA Registration Assistance delivers a detailed compliance report identifying all issues found — with clear, actionable recommendations for correcting labeling deficiencies before your product reaches the market.
Revised Label Confirmed Compliant
After corrections are made, FDA Registration Assistance confirms your revised label meets all applicable FDA requirements — ensuring your drug product is ready for distribution without compliance risk.
What Every Drug Labeler Must Do Before Print
Under 21 CFR Part 201 and FD&C Act §502, every firm whose name appears on a drug product label carries concrete pre-market compliance duties — failure on any one of them can render the product misbranded.
Use the Correct Drug Facts Panel Format
OTC drug products must display the Drug Facts panel exactly as specified in 21 CFR 201.66 — fixed heading order (Active ingredient, Purpose, Uses, Warnings, Directions, Other information, Inactive ingredients, Questions), minimum type sizes, bullet styles, bold headings, and panel borders.
Declare Established Names & Strengths Correctly
Active ingredients must be listed by the FDA-recognized established name (USAN or USP) with the per-dose quantity. Inactive ingredients must appear in alphabetical order per 21 CFR 201.66(c)(8). Trade names, marketing names, and generic abbreviations cannot replace the established name.
Match the Applicable OTC Monograph
Sunscreens (21 CFR 352), antiseptics (21 CFR 333), antiperspirants (21 CFR 350), acne products (21 CFR 333), pain relievers, and dandruff products each have their own monograph specifying allowed ingredients, dosages, indications, and required warnings. The label must match the monograph verbatim where required.
Include All Mandatory Warnings
The Drug Facts Warnings section must contain every monograph-mandated warning, plus general warnings under 21 CFR 201.66(c)(5) — Keep out of reach of children, do not use, ask a doctor before use, when using this product, stop use and ask a doctor, and pregnancy/nursing precautions where applicable.
Display the Principal Display Panel Correctly
Under 21 CFR 201.62, the principal display panel must show the established product name, intended use, net quantity of contents, and active ingredient — in type sizes proportional to the panel area. The PDP is the part of the label most likely to be displayed at retail.
Show NDC, Lot Number & Expiration Date
Every dispensed package must show the NDC, a lot or control number for traceability under 21 CFR 211.130, and an expiration date supported by stability data under 21 CFR 211.137. The NDC on the label must match the NDC registered in the FDA SPL drug listing.
Keep Claims Truthful, Substantiated & Non-Misleading
Under FD&C Act §502(a), every claim — efficacy, comparative, "clinically proven," "doctor recommended," "natural" — must be truthful, non-misleading, and substantiated by competent and reliable evidence. Unapproved disease claims convert an OTC drug into an unapproved new drug under §505.
Use English & the Correct Country-of-Origin Marking
21 CFR 201.15 requires all FDA-required labeling in English; additional languages are permitted but never sufficient on their own. Imported drugs must also carry conspicuous country-of-origin marking under 19 CFR Part 134 enforced by U.S. Customs and Border Protection.
Drug Label Review vs. Dietary Supplement Label Review
These two FDA label review services are constantly confused — but they're regulated by different FDA centers, governed by different CFR parts, and use entirely different label formats. Mixing them up is one of the fastest paths to misbranding.
| Attribute | FDA Drug Label & Ingredient Review | Dietary Supplement Label Review |
|---|---|---|
| Who Designates It | FDA's Center for Drug Evaluation and Research (CDER) sets the labeling standard the reviewer applies | FDA's Center for Food Safety and Applied Nutrition (CFSAN) sets the labeling standard the reviewer applies |
| Who It Represents | OTC and prescription drug products — anything labeled as a drug under FD&C Act §201(g) | Dietary supplements regulated under DSHEA — vitamins, minerals, herbs, amino acids, botanicals |
| Required By | FD&C Act §502 + 21 CFR Part 201 for every drug marketed in the U.S. | FD&C Act §403 + 21 CFR Part 101 for every supplement marketed in the U.S. |
| Governing Regulation | 21 CFR Part 201 · Drug Facts panel under 21 CFR 201.66 | 21 CFR 101.36 · Supplement Facts panel |
| Primary Function | Verify drug claims, dosage instructions, warnings, and monograph compliance to prevent misbranding | Verify supplement structure/function claims, daily value declarations, and DSHEA disclaimer |
| Required For | OTC sunscreens, hand sanitizers, pain relievers, antiseptics, prescription drugs, OTC monograph products | Multivitamins, herbal extracts, sports nutrition powders, probiotics, mineral tablets |
A "Drug Facts" panel on a supplement, or a "Supplement Facts" panel on an OTC drug, is itself a misbranding violation — because each falsely represents the product as the other category. Many brands operate in both spaces (an OTC pain reliever and a turmeric supplement, for example), and each product must be reviewed under its own framework: drugs against 21 CFR Part 201, supplements against 21 CFR Part 101. FDA Registration Assistance provides this Drug Label & Ingredient Review under the Part 201 framework; supplement labels go through a separate Supplement Facts review service. Most full-line brands ultimately need both review tracks running in parallel.
In-House Review vs. FDA Registration Assistance
FDA labeling rules are public — but reading 21 CFR Part 201, the relevant OTC monograph, and current FDA guidance against a real drug artwork is a specialist task. Here's the trade-off.
| Factor | In-House / Marketing Team Review | Recommended FDA Registration Assistance |
|---|---|---|
| Cost | $0 direct fee + internal hours, recall risk, relabeling costs, marketplace delisting fallout | $249 USD per label — written compliance report plus post-revision verification |
| Availability | Dependent on whoever in-house is "free" — typically marketing, not regulatory affairs | Dedicated FDA regulatory specialist assigned to the review, U.S. business hours |
| Domain Expertise | Requires deep knowledge of 21 CFR Part 201, the applicable OTC monograph, FDA guidance, and recent Warning Letters | 15+ years of OTC monograph, Drug Facts, sunscreen, sanitizer, and Rx PLR label reviews |
| Risk of Misbranding | High — wrong established names, missing warnings, off-monograph claims, and PDP errors are common | Pre-revision audit catches every monograph and Part 201 deficiency before print |
| Confirmation & Handling | Marketing approves the artwork and prints it — there is no FDA-aware sign-off | Written compliance report plus a final sign-off on the corrected label |
| Update Tracking | You must monitor FDA guidance updates, Warning Letters, and monograph changes yourself | Re-review on demand whenever formulation, claims, or FDA guidance changes |
In-house teams almost always staff label work with marketing or graphic-design talent — not regulatory specialists. The result is well-designed labels that miss the established ingredient name, the mandatory monograph warning, or the principal display panel requirement, and only get caught after FDA enforcement, an Amazon category audit, or a CBP detention at U.S. ports. A $249 pre-print review by FDA Registration Assistance is a small fraction of the cost of recovery from any of those events.
Free / Friend Review vs. FDA Registration Assistance
The FDA does not pre-approve OTC drug labels and does not charge for label review. You can have anyone read your artwork — but only an FDA regulatory specialist can verify it against the actual standard.
| Factor | Free / Friend / Agency Opinion | Recommended FDA Registration Assistance |
|---|---|---|
| Government Fee | $0 — the FDA does not pre-approve OTC labels and charges no review fee | $0 government fee + $249 service per label (full written compliance report) |
| Pros | No out-of-pocket cost; fast informal feedback from someone you already know | Specialist review against 21 CFR Part 201 + the actual applicable OTC monograph, with written documentation |
| Cons | A non-specialist cannot verify monograph compliance, established names, warning sequence, principal display panel rules, or recent FDA guidance — and gives you no defensible documentation if FDA later challenges the label | Predictable cost, defensible written report, follow-through on corrections, and final sign-off |
| Best For | Pre-decision sanity checks only — not a substitute for a regulatory review | Every OTC, OTC monograph, and Rx drug product before artwork goes to print or before marketplace listing |
A "free" friend or generalist agency review feels like a shortcut — but it almost always misses the regulatory-specific issues that the FDA, CBP, and Amazon actually flag: wrong established names, off-monograph claims, missing warning sequences, and Drug Facts panel format errors. The actual government fee is $0; the value of a professional review is the trained eye reading against the standard.
Drug Labeling Terms You Will Encounter
A quick reference of the technical terms, panels, and standards used throughout the FDA drug label review process.
The standardized labeling format required on OTC drug products under 21 CFR 201.66 — fixed headings (Active ingredient, Purpose, Uses, Warnings, Directions, Other information, Inactive ingredients, Questions) in a defined order, type size, and style.
The part of the label most likely to be displayed or examined at retail. Under 21 CFR 201.62, it must show the established product name, intended use, net quantity, and active ingredient in proportional type sizes.
An FDA Order (post-CARES Act) that establishes the allowed ingredients, dosages, indications, warnings, and labeling for a specific category of non-prescription drug — e.g., sunscreens (21 CFR 352), antiseptics (21 CFR 333), antiperspirants (21 CFR 350).
The official non-proprietary name of a drug substance under FD&C Act §502(e) — typically the USAN or USP name (e.g., "ibuprofen," "acetaminophen"). Must be used on the label; trade names alone are not sufficient.
The drug substance responsible for the product's pharmacological effect. Must be declared on the Drug Facts panel by established name with the quantity per dosage unit.
All non-active components of the formulation. Must be listed in alphabetical order on the OTC Drug Facts panel under 21 CFR 201.66(c)(8); colors are typically listed in a separate sub-clause.
A drug is misbranded under FD&C Act §502 if its labeling is false or misleading, missing required information, in the wrong format, or makes unsubstantiated claims. Misbranded drugs are barred from interstate commerce.
The Highlights/Full Prescribing Information format required for prescription drug labeling under 21 CFR 201.56–201.57. Includes Boxed Warning, Indications & Usage, Dosage and Administration, Contraindications, Warnings and Precautions, Adverse Reactions, and more.
See above. Distinct from the back/info panel that carries the Drug Facts box. The PDP carries the brand, established name, intended use, and net quantity.
The three-segment FDA product identifier (Labeler Code + Product Code + Package Code) that must appear on the drug label. The printed NDC must match the SPL drug listing in the FDA NDC Directory.
A traceability code required on every drug package under 21 CFR 211.130 so the manufacturer can identify the production batch in case of recall or adverse-event investigation.
The date through which the product is expected to meet specifications when stored per labeled conditions. Must appear on the label and be supported by stability data under 21 CFR 211.137.
Why Drug Labels Fail FDA Review & Marketplace Audits
After 15+ years of drug label reviews, these are the most common reasons OTC and Rx labels are flagged by the FDA, CBP, Amazon, or Walmart.
Trade Name Used Instead of Established Name
The Drug Facts panel must list the active ingredient by its FDA-recognized established name (e.g., "acetaminophen," not "Brand-X Pain Reliever"). Using only the trade name is a §502(e) violation flagged by every FDA reviewer.
Off-Monograph Claims or Indications
Sunscreen labels claiming "anti-aging," sanitizer labels claiming "kills COVID-19," or pain reliever labels claiming "cures arthritis" exceed the applicable monograph — converting the product into an unapproved new drug under FD&C Act §505.
Missing Mandatory Warnings
Every Drug Facts panel must include 21 CFR 201.66(c)(5) general warnings (Keep out of reach of children, etc.) plus all monograph-specific warnings. Missing any required warning makes the product misbranded the moment it ships.
Drug Facts Panel Out of Order or Wrong Format
21 CFR 201.66 prescribes the exact heading order, type size, bullet style, and panel border. Resequencing headings, dropping the bold "Drug Facts" title, or using non-conforming type is one of the most common reasons artwork is rejected.
Inactive Ingredients Not in Alphabetical Order
Inactive ingredients must appear in alphabetical order on the OTC Drug Facts panel per 21 CFR 201.66(c)(8). Brands routinely list ingredients in "marketing-friendly" order, which is a misbranding flag the FDA cites frequently.
Principal Display Panel Missing Active Ingredient or Net Quantity
Under 21 CFR 201.62, the PDP must show the active ingredient and the net quantity of contents in proportional type. Omitting either is a §502 violation routinely cited in FDA Warning Letters and Amazon category-gating audits.
NDC on Label Does Not Match the SPL Drug Listing
If the printed NDC differs from the NDC registered in the FDA SPL drug listing, pharmacy adjudication rejects the claim and Amazon delists the product. The label must reflect the NDC published in the FDA NDC Directory.
"FDA-Approved" or "Doctor Recommended" Claims Without Substantiation
Claims like "FDA-approved" on a non-approved drug, or "doctor recommended" without survey data, violate FD&C Act §502(a) and FTC Act §5. They are flagged in FDA Warning Letters and FTC enforcement actions and trigger marketplace removal.
Complete FDA Drug Registration Solutions
We offer a full range of FDA registration and compliance services to help your facility and shipments meet all U.S. regulatory requirements.
Drug Establishment Registration
Register your foreign or domestic drug manufacturing, repacking, or relabeling facility with the FDA — $449/year, U.S. Agent included.
Labeler Code Registration
Obtain your FDA Labeler Code — required to identify your company on drug product labels and NDC numbers. $349 per company.
NDC Code / Product Code
Register your National Drug Code (NDC) and product codes with the FDA — $199 per product, mandatory for all U.S. drug products.
Drug Label & Ingredient Review
Ensure your drug product labels and ingredient declarations meet all FDA labeling requirements before entering the U.S. market.
DUNS Request Assistance
Obtain your DUNS Number required for FDA Drug Establishment Registration and federal compliance — filed accurately on your behalf.
Drug / OTC U.S. Agent Services
Designate a U.S. FDA Agent for your foreign drug establishment — legally required for all foreign drug facilities registered with the FDA.
FDA Drug Listing Certificate
Obtain your official FDA Drug Listing Certificate confirming your drug product is registered and listed with the U.S. Food and Drug Administration.
FDA Drug Master Files (DMF)
Submit an FDA Drug Master File (DMF) to protect confidential manufacturing information while supporting drug product applications and registrations.
Drug Import Alert Removal
Get expert help resolving FDA drug import alerts and detentions to restore your drug products' ability to enter the United States.
Frequently Asked Questions About Drug Label & Ingredient Review
Find answers to the most common questions about FDA drug labeling requirements, OTC Drug Facts Labels, ingredient compliance, and how FDA Registration Assistance helps keep your products market-ready.
What is the FDA Drug Facts Label?
The FDA Drug Facts Label is the standardized labeling format required for OTC drug products marketed in the United States. Established under 21 CFR Part 201, it presents active ingredients, uses, warnings, directions, and other information in a uniform, consumer-friendly format. FDA Registration Assistance reviews your OTC drug labels to ensure full Drug Facts Label compliance.
Who must comply with FDA drug labeling requirements?
All manufacturers, repackagers, relabelers, and distributors of OTC and prescription drug products marketed in the United States must comply with FDA drug labeling requirements. FDA Registration Assistance assists both domestic and foreign drug companies in ensuring their labels meet all applicable FDA standards.
What does FDA Registration Assistance review in a drug label?
FDA Registration Assistance reviews your drug product label for compliance with FDA format requirements, required headings and sections, active and inactive ingredient listings, warning statements, usage directions, claims, contraindications, and overall Drug Facts Label structure. Our review identifies all compliance gaps before your product enters the market.
What are the consequences of non-compliant drug labeling?
Non-compliant drug labeling can result in FDA misbranding violations, import detentions, product recalls, mandatory relabeling, and removal from the market. FDA Registration Assistance helps you identify and correct labeling issues before they result in regulatory action or distribution delays.
Does my OTC drug label need to follow the Drug Facts Label format?
Yes. The vast majority of OTC drug products marketed in the United States are required to use the FDA Drug Facts Label format, established in the Federal Register of March 1999 and effective since May 2002. The format applies to more than 100,000 OTC drug products currently on the market. FDA Registration Assistance reviews your label against these requirements.
What is an OTC monograph and how does it affect my label?
An OTC monograph is an FDA regulation that defines the acceptable active ingredients, dosages, formulations, and labeling requirements for specific OTC drug categories. Your product label must comply with the applicable OTC monograph for your drug category. FDA Registration Assistance reviews your label against the relevant monograph requirements to ensure compliance.
Do I need to list both active and inactive ingredients on my drug label?
Yes. FDA drug labeling requirements mandate the declaration of all active ingredients with their established names and amounts, as well as inactive ingredients listed in alphabetical order. FDA Registration Assistance reviews your ingredient declarations to ensure they are complete, accurately formatted, and compliant with FDA requirements.
When does my drug label need to be updated?
Drug labels must be updated whenever there are changes to the product's formulation, active or inactive ingredients, strength, dosage form, claims, warnings, or applicable FDA guidance and regulations. FDA Registration Assistance reviews updated labels to confirm all changes meet current FDA requirements before the product re-enters the market.
Can FDA Registration Assistance review labels for foreign drug products entering the U.S.?
Yes. FDA Registration Assistance reviews drug product labels for both domestic and foreign manufacturers, repackagers, and distributors seeking to enter the U.S. market. We have assisted companies in over 135 countries in ensuring their drug labels meet FDA requirements before commercial distribution in the United States.
Does FDA Registration Assistance review prescription drug labels as well as OTC?
Yes. FDA Registration Assistance reviews both OTC drug product labels (Drug Facts Label format) and prescription drug product labels for compliance with applicable FDA labeling requirements under 21 CFR Part 201. Contact FDA Registration Assistance to discuss your specific drug product labeling review needs.
What information do I need to provide for a label review?
FDA Registration Assistance requires your drug product label artwork or text, complete ingredient list (active and inactive), product name, intended use, dosage form, and strength. FDA Registration Assistance will review all provided materials against current FDA labeling requirements and provide a detailed compliance report.
How much does a drug label review cost through FDA Registration Assistance?
FDA Registration Assistance charges $249 USD per label review — including a full review of your label format, ingredient declarations, claims, warnings, and compliance with applicable FDA requirements. Contact FDA Registration Assistance today to get started and ensure your drug product is market-ready.
How long does a drug label review take?
FDA Registration Assistance typically completes drug label reviews promptly, with turnaround depending on the complexity of the product and label. Contact FDA Registration Assistance to discuss your timeline and ensure your drug product review is completed before your planned market launch date.
What is a misbranding violation and how can I avoid it?
A misbranding violation occurs when a drug product's label is false, misleading, incomplete, or fails to meet FDA format and content requirements. Misbranded products can be seized, recalled, or barred from importation. FDA Registration Assistance reviews your labels proactively to identify and correct any issues that could result in a misbranding determination.
Does FDA Registration Assistance provide recommendations for correcting label issues?
Yes. FDA Registration Assistance provides a detailed compliance report with clear, actionable recommendations for correcting any labeling deficiencies identified during review. Our goal is to ensure your label is fully FDA-compliant before your drug product reaches the market — minimizing regulatory risk and avoiding costly delays.
Can FDA Registration Assistance help with both label review and drug establishment registration?
Yes. FDA Registration Assistance provides a full range of FDA drug compliance services — including Drug Establishment Registration, Labeler Code Assignment, NDC Code Registration, Drug Label & Ingredient Review, and ongoing compliance support. Contact FDA Registration Assistance to discuss your complete FDA compliance needs.
What does the $249 per-review fee cover, and how does it stack with Drug Establishment Registration, Labeler Code, and NDC Code services?
The $249 covers a complete written compliance review of one drug product label and ingredient declaration against 21 CFR Part 201, the applicable OTC monograph, FD&C Act §502 misbranding standards, and current FDA labeling guidance — including a written deficiency report and post-revision verification of the corrected label. Most drug companies sequence the four core services together: Drug Establishment Registration at $449/year (under 21 CFR Part 207, with U.S. Agent included), Drug Labeler Code at $349 (under 21 CFR 207.33), NDC Code / Product Code at $199 per product, and Drug Label & Ingredient Review at $249 per label. A typical first-launch package for one product is $449 + $349 + $199 + $249 = $1,246, and only the Drug Establishment Registration renews annually.
Can a friend, marketing agency, or unrelated party do my FDA drug label review?
Technically anyone can write copy on a drug label, but only FDA regulatory specialists are equipped to verify that the label complies with 21 CFR Part 201, the relevant OTC monograph, FD&C Act §502, and current FDA guidance. A friend or generalist agency typically does not know which active ingredient names are "established names" under USAN, where the Drug Facts panel must appear, which warnings the monograph mandates, or which claims constitute misbranding. A non-specialist review almost always results in misbranded labels reaching the market — triggering FDA warning letters, import refusal, marketplace delisting, and costly relabeling. FDA Registration Assistance performs the review against the actual regulatory standard.
What happens if the FDA finds problems with my drug label after the product is already on the market?
The product is deemed misbranded under FD&C Act §502, and the FDA can issue a Warning Letter requiring corrective action, place the product on Import Alert, demand a voluntary or mandatory recall, refuse shipments at U.S. ports, and refer egregious cases to DOJ for prosecution under 21 U.S.C. §333. Marketplaces such as Amazon, Walmart, and Shopify routinely cross-check FDA enforcement actions and delist products with active Warning Letters or recalls. A pre-market review at $249 is dramatically less expensive than recovering from any of these enforcement outcomes.
How do I update or change a drug label on a product I've already launched?
Update the artwork, re-verify the revised label against the current monograph and 21 CFR Part 201, then file an SPL drug listing amendment through CDER Direct so the FDA's NDC Directory reflects the new labeling. Any change to active ingredients, strength, dosage form, indication, warnings, or directions requires the SPL update; cosmetic-only changes (color, logo placement) generally do not. FDA Registration Assistance reviews the revised label, prepares the SPL amendment, and submits it through the FDA Electronic Submissions Gateway so the printed label and the FDA record stay in sync.
Do I need an FDA label review to sell my OTC sunscreen or hand sanitizer on Amazon?
Effectively yes. Amazon's OTC drug categories — sunscreens, hand sanitizers, acne products, pain relievers, topical antiseptics — require sellers to provide a compliant Drug Facts Label, valid NDC, and FDA Labeler Code before listings go live. Amazon's category-gating reviewers reject labels with missing 'Drug Facts' panels, wrong active ingredient names, missing warnings, or off-monograph claims. A pre-launch FDA label review prevents listing rejection and account suspension.
Does a label review by FDA Registration Assistance mean my drug is FDA-approved?
No. A label review confirms that the label meets FDA format and content requirements — it is not FDA approval, clearance, or endorsement of the drug. 21 CFR 207.77 explicitly prohibits any statement that registration, listing, an NDC, or a Labeler Code implies FDA approval. Marketing copy that claims "FDA-approved" based on a label review or NDC is itself a misbranding violation under FD&C Act §502(a).
Do dietary supplements need an FDA Drug Facts Label?
No. Dietary supplements use the Supplement Facts panel under 21 CFR 101.36 and are regulated by FDA's CFSAN under DSHEA, not as drugs. A "Drug Facts" panel on a supplement label is itself misbranding because it falsely represents the product as an OTC drug. FDA Registration Assistance reviews drug labels (Drug Facts and Rx labeling) — supplement labels are reviewed under a separate Supplement Facts review service.
Are homeopathic drug products required to comply with the Drug Facts Label format?
Yes. Per FDA guidance, OTC homeopathic drugs marketed in the U.S. are subject to the same 21 CFR 201.66 Drug Facts Label requirements as any other OTC drug — including active ingredients (HPUS names with potency), uses, warnings, and directions. Homeopathic claims must also comply with FDA enforcement priorities and FTC truth-in-advertising rules.
Are private label and contract-manufactured drug labels reviewed the same way?
Yes. The label belongs to the labeler-of-record (the firm whose name appears on the package), not the contract manufacturer. The labeler-of-record carries full responsibility for FDA compliance under 21 CFR Part 201. Private label brand owners must verify the label against the monograph independently — they cannot rely on the contract manufacturer's labeling decisions.
Are "natural", "clinically proven", or "doctor recommended" claims allowed on OTC drug labels?
Only with substantiation. Under FD&C Act §502(a), any claim must be truthful, non-misleading, and adequately substantiated. "Natural" is unregulated and considered misleading on most OTC drugs. "Clinically proven" requires controlled clinical evidence. "Doctor recommended" requires documented survey data. Unsubstantiated claims trigger FDA Warning Letters and FTC enforcement.
Does my drug label need to include a Material Code, lot number, and expiration date?
Yes for lot and expiration. 21 CFR 201.18 and 21 CFR 211.137 require an expiration date supported by stability data, and 21 CFR 211.130 requires lot or control number traceability on every package. The NDC must also appear on the label. A material code is not separately required, but the NDC, lot, and expiration are all FDA-mandated and routinely flagged when missing.
Can a drug label be in Spanish (or another language) only?
No. Under 21 CFR 201.15, all required labeling must appear in English. Additional languages are permitted as long as the English version is complete and prominent. Spanish-only or other foreign-language-only OTC drug labels are deemed misbranded — including products sold in Puerto Rico and Spanish-language Amazon listings.
Does the Drug Facts Label need to appear on the outer carton, the inner container, or both?
Both, in most cases. Under 21 CFR 201.66, the Drug Facts panel must appear on the outer carton and on any immediate container that is dispensed to the consumer — including bottles, blister packs, and tubes. Small package exemptions exist but are narrow. The principal display panel must also show the product name, active ingredient, net quantity, and intended use.
Are "made in USA" or country-of-origin claims allowed on drug labels?
Conditionally. Country-of-origin marking is required under 19 CFR Part 134 (CBP) for imported drugs. "Made in USA" claims are regulated by the FTC and require that "all or virtually all" of the product is made in the U.S. Misuse of either claim on a drug label is misbranding under FD&C Act §502(a) and an unfair-trade-practices violation under the FTC Act.
Get Your Drug Label Reviewed Today
Submit your drug product label and ingredient details and FDA Registration Assistance will conduct a full compliance review against current FDA requirements — identifying any labeling issues and providing clear recommendations before your product reaches the market.
Thank You for Reaching Out!
We've received your message and will get back to you within 24 hours. If you need immediate assistance, please call us directly.